SW620 cell viability

SW620 cell viability is a phenotypic readout used in preclinical oncology research to measure the health, metabolic activity, and proliferation of the SW620 human colorectal adenocarcinoma cell line in response to drug treatment [1][8]. The SW620 line is a well-characterized model for metastatic colorectal cancer, originally isolated from a lymph node metastasis in a 51-year-old patient with Dukes stage C disease [2][4]. It is frequently paired with the SW480 cell line, derived from the same patient's primary tumor, to study the molecular transitions involved in cancer progression and metastasis [7]. Molecularly, SW620 cells are defined by critical mutations in the KRAS (G12V) oncogene and the TP53 (R273H) tumor suppressor, which drive their aggressive growth and resistance to certain therapies [2][10]. Assays quantifying SW620 cell viability, such as MTT, MTS, or ATP bioluminescence, allow researchers to evaluate the cytotoxic potential of novel chemotherapeutics and identify inhibitors of survival pathways like Wnt/β-catenin and PI3K/AKT [8][9][14]. Because these cells represent an advanced, metastatic phenotype, changes in their viability serve as a primary indicator for therapeutic efficacy in late-stage colorectal cancer drug discovery [7][15].

Other names

SW-620 cell viabilitySW620 cytotoxicitySW620 proliferationSW620 cell survival

Induction of programmed cell death (apoptosis), generation of reactive oxygen species (ROS), inhibition of the Wnt/β-catenin signaling pathway, and suppression of focal adhesion kinase (FAK) and hyaluronan synthase (HAS) activity [9][12][13].